LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Developing AI systems to discover and design new materials for clean energy and chipmaking
Builds quantum computers using lasers to hold individual atoms in place
Building a unified robotics foundation model for controlling robots